Status:
COMPLETED
Reasons for Mycophenolate Mofetil Dose Reduction and Impact on Graft Outcome in Renal Transplant Recipients
Lead Sponsor:
Universitaire Ziekenhuizen KU Leuven
Conditions:
Acute Rejection of Renal Transplant
Renal Graft Loss
Eligibility:
All Genders
18+ years
Brief Summary
Mycophenolate mofetil (MMF) decreases the risk of acute rejection and is associated with improved graft survival in renal transplant recipients. However, MMF-related side effects often necessitate dos...
Eligibility Criteria
Inclusion
- All patients who received a single renal transplant at the University Hospitals of Leuven between April 1996 (when MMF was introduced in the Leuven renal transplant program) and February 2007 and were treated with MMF (Cellcept®, Roche) as part of their initial maintenance immunosuppressive regimen were included in this retrospective analysis.
Exclusion
- If a patient underwent more than one kidney transplantation in the abovementioned 11-year period, only the last was considered.
Key Trial Info
Start Date :
January 1 1996
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
749 Patients enrolled
Trial Details
Trial ID
NCT01496703
Start Date
January 1 1996
End Date
December 1 2008
Last Update
December 21 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitaire Ziekenhuizen Leuven
Leuven, Belgium, 3000